[go: up one dir, main page]

PE20090972A1 - Inhibidores de quinasa c-fms - Google Patents

Inhibidores de quinasa c-fms

Info

Publication number
PE20090972A1
PE20090972A1 PE2008001797A PE2008001797A PE20090972A1 PE 20090972 A1 PE20090972 A1 PE 20090972A1 PE 2008001797 A PE2008001797 A PE 2008001797A PE 2008001797 A PE2008001797 A PE 2008001797A PE 20090972 A1 PE20090972 A1 PE 20090972A1
Authority
PE
Peru
Prior art keywords
exo
oct
dimethyl
hydroxy
cyane
Prior art date
Application number
PE2008001797A
Other languages
English (en)
Inventor
Carl R Illig
Jinsheng Chen
Sanath K Meegalla
Mark J Wall
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20090972A1 publication Critical patent/PE20090972A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE W ES DE PREFERENCIA 4-CIANO-1H-IMIDAZOL; R2 ES CICLOALQUILO, TIOFENILO, FENILO, FURANILO, ENTRE OTROS; Z ES H, F, Cl, CH3; J ES CH, N; X ES 3-EXO-3-HIDROXI-1,5-BIS-HIDROXIMETIL-8-OXA-BICICLO[3.2.1]OCT-6-EN-3-IL, 3-ENDO-1,5-BIS-METOXIMETIL-8-OXA-BICICLO[3.2.1]OCT-3-IL, 3-EXO-3-HIDROXI-1,5-DIMETIL-6-EXO,7EXO-(DIMETILMETILENDIOXI)-BICICLO[3.2.1]OCT-3-IL, ENTRE OTROS.SON COMPUESTOS PREFERIDOS: [2-(4,4-DIMETIL-CICLOHEX-1-ENIL)-4-[(3-EXO)-3-HIDROXI-1,5-BIS-METOXIMETIL-8-OXA-BICICLO[3.2.1]OCT-6-EN-3-IL]-FENIL]-AMIDA DEL ACIDO 4-CIANO-1-H-IMIDAZOL-2-CARBOXILICO; ESTER METILICO DEL ACIDO 3-(3-EXO)-[4-[(4-CIANO-1H-IMIDAZOL-2-CARBONIL)-AMINO]-3-(4,4-DIMETIL-CICLOHEX-1-ENIL)-FENIL]-(3-EXO)-3-HIDROXI-1,5-DIMETIL-8-AZA-BICICLO[3.2.1]OCT-6-EN-8-CARBOXILICO; ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE TIROSINA QUINASA c-fms, UTILES EN EL TRATAMIENTO DE OSTEOPOROSIS, ENEFERMEDAD pAGET, SARCOMA, MIELOMA, ENTRE OTRAS
PE2008001797A 2007-10-17 2008-10-17 Inhibidores de quinasa c-fms PE20090972A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98062307P 2007-10-17 2007-10-17

Publications (1)

Publication Number Publication Date
PE20090972A1 true PE20090972A1 (es) 2009-07-13

Family

ID=40352814

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001797A PE20090972A1 (es) 2007-10-17 2008-10-17 Inhibidores de quinasa c-fms

Country Status (36)

Country Link
US (1) US8497376B2 (es)
EP (2) EP2215079B1 (es)
JP (1) JP5475672B2 (es)
KR (1) KR101559326B1 (es)
CN (1) CN101889009B (es)
AR (1) AR068892A1 (es)
AU (1) AU2008312540B2 (es)
BR (1) BRPI0817843B8 (es)
CA (1) CA2702898C (es)
CL (1) CL2008003068A1 (es)
CO (1) CO6270363A2 (es)
CR (1) CR11433A (es)
CY (2) CY1118717T1 (es)
DK (2) DK3208269T3 (es)
EA (1) EA018936B1 (es)
ES (2) ES2905118T3 (es)
HR (2) HRP20211593T1 (es)
HU (2) HUE031555T2 (es)
IL (1) IL205043A (es)
JO (1) JO3240B1 (es)
LT (2) LT2215079T (es)
MX (1) MX2010004263A (es)
MY (1) MY153951A (es)
NI (1) NI201000059A (es)
NZ (1) NZ584574A (es)
PA (1) PA8799701A1 (es)
PE (1) PE20090972A1 (es)
PL (2) PL3208269T3 (es)
PT (2) PT2215079T (es)
RS (2) RS55860B1 (es)
SI (2) SI2215079T1 (es)
TW (1) TWI440637B (es)
UA (1) UA99311C2 (es)
UY (1) UY31397A1 (es)
WO (1) WO2009052237A1 (es)
ZA (1) ZA201003429B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
EP2021335B1 (en) 2006-04-20 2011-05-25 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
US8697716B2 (en) * 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
ES2565238T3 (es) 2006-04-20 2016-04-01 Janssen Pharmaceutica N.V. Inhibidores de la c-fms quinasa
TWI619713B (zh) * 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
US20120271046A1 (en) 2011-04-19 2012-10-25 Jeffrey Christopher S Nitrogen-containing heterocyclic compounds and methods of making the same
US9303046B2 (en) * 2012-08-07 2016-04-05 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) * 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2885278B1 (en) 2012-08-16 2016-08-03 Janssen Pharmaceutica N.V. Substituted pyrazoles as n-type calcium channel blockers
PT2970232T (pt) 2013-03-15 2018-05-09 Janssen Pharmaceutica Nv Derivados de piridina substituída úteis como inibidores de cinase c-fms
WO2014151253A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide for the treatment of hodgkin's lymphoma
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
SG11201600846WA (en) * 2013-08-16 2016-03-30 Janssen Pharmaceutica Nv Substituted imidazoles as n-type calcium channel blockers
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
WO2015094970A1 (en) * 2013-12-19 2015-06-25 Archer Daniels Midland Company Mono- and dialkyl ethers of furan-2,5-dimethanol and (tetra-hydrofuran-2,5-diyl)dimethanol and amphiphilic derivatives thereof
JP6537338B2 (ja) * 2015-04-24 2019-07-03 日東電工株式会社 核酸固相合成用リンカー及び担体
KR20180107142A (ko) * 2016-02-11 2018-10-01 바이엘 크롭사이언스 악티엔게젤샤프트 해충 방제제로서의 치환된 2-옥시이미다졸릴-카르복스아미드
TW201811326A (zh) 2016-07-18 2018-04-01 比利時商健生藥品公司 ４－氰基－ｎ－（２－（４，４－二甲基環己－１－烯－１－基）－６－（２，２，６，６－四甲基四氫－２ｈ－哌喃－４－基）吡啶－３－基）－１ｈ－咪唑－２－甲醯胺之鹽形式
TWI752980B (zh) * 2016-07-18 2022-01-21 比利時商健生藥品公司 4-氰基-n-(2-(4,4-二甲基環己-1-烯-1-基)-6-(2,2,6,6-四甲基四氫-2h-哌喃-4-基)吡啶-3-基)-1h-咪唑-2-甲醯胺之晶型
US10857230B2 (en) 2017-03-03 2020-12-08 Janssen Biotech, Inc. Co-therapy comprising a small molecule CSF-1R inhibitor and an agonistic antibody that specifically binds CD40 for the treatment of cancer
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
WO2020222109A1 (en) 2019-05-02 2020-11-05 Janssen Biotech, Inc. Csf-1/csf-1r gene set
CN110575450B (zh) * 2019-09-17 2023-03-31 遵义医科大学珠海校区 2,5-呋喃二甲醇在制备抗肿瘤药物中的应用
WO2021144360A1 (en) 2020-01-17 2021-07-22 F. Hoffmann-La Roche Ag Small molecule csf-1r inhibitors in therapeutic and cosmetic uses
WO2024254440A1 (en) * 2023-06-09 2024-12-12 Modulo Bio, Inc. 5-cyano-1h-imidazole-2-carboxamide compounds as csf1r inhibitors

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2466420A (en) * 1947-11-26 1949-04-05 Eastman Kodak Co Ketene condensation products with aldehydes
US3226394A (en) * 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
CH504416A (de) 1966-12-05 1971-03-15 Ciba Geigy Ag Verfahren zur Herstellung von aromatischen Sulfamoylverbindungen
US4551540A (en) 1983-01-17 1985-11-05 Borg-Warner Chemicals, Inc. Substituted 2,5-dimethylpyrroles
US5190541A (en) * 1990-10-17 1993-03-02 Boston Scientific Corporation Surgical instrument and method
CA2452130A1 (en) * 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5686472A (en) 1992-10-29 1997-11-11 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
EP0785937A1 (en) 1994-10-14 1997-07-30 Smithkline Beecham Plc 2-(imidazol-4-yl)carbapeneme derivatives, intermediates thereof and use as antibacterials
KR19990007865A (ko) 1995-04-19 1999-01-25 스피겔알렌제이 약물 방출용 피복 스텐트
US6117432A (en) * 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
WO1997021701A1 (en) * 1995-12-08 1997-06-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5702390A (en) * 1996-03-12 1997-12-30 Ethicon Endo-Surgery, Inc. Bioplar cutting and coagulation instrument
AU711936B2 (en) 1996-08-09 1999-10-28 Banyu Pharmaceutical Co., Ltd. Stereoselective deoxygenation reaction
EP0946565B1 (en) 1996-12-20 2003-10-15 Tovarischestvo S Ogranichennoi Otvetstvennostju "Tabifarm" Method and device for production of lyophilized hydrochloride-1ss, 10ss-epoxy-13-dimethylamino-guaia-3(4)-en-6,12-olide
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
HUP0001122A3 (en) 1997-04-25 2002-03-28 Janssen Pharmaceutica Nv Farnesyltransferase inhibiting quinazolinones
TW491872B (en) 1997-05-27 2002-06-21 Ciba Sc Holding Ag Block oligomers containing l-hydrocarbyloxy-2,2,6,6-tetramethyl-4- piperidyl groups as stabilizers for lower polyolefin
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
ES2176012T3 (es) 1998-03-05 2002-11-16 Formula One Administration Ltd Sistema de comunicacion de datos.
US6303654B1 (en) 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
WO2000001691A1 (en) 1998-07-01 2000-01-13 Merck & Co., Inc. Process for making farnesyl-protein transferase inhibitors
CA2336848A1 (en) 1998-07-10 2000-01-20 Merck & Co., Inc. Novel angiogenesis inhibitors
ATE321037T1 (de) 1998-08-27 2006-04-15 Pfizer Prod Inc Als antikrebsmittel verwendbare alkinyl- substituierte chinolin-2-on-derivate
ES2237125T3 (es) 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
TW531533B (en) 1998-12-23 2003-05-11 Janssen Pharmaceutica Nv 1,2-annelated quinoline derivatives having farnesyl transferase and geranylgeranyl transferase inhibiting activity
EP1140938B1 (en) 1999-01-11 2003-08-27 Princeton University High affinity inhibitors for target validation and uses thereof
HUP0202708A3 (en) * 1999-04-15 2004-12-28 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
ATE269357T1 (de) * 1999-04-28 2004-07-15 Univ Texas Zusammensetzungen und verfahren zur krebsbehandlung durch die selektive hemmung von vegf
US6346625B1 (en) * 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
WO2001047897A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
FR2803592A1 (fr) 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
US6558385B1 (en) * 2000-09-22 2003-05-06 Tissuelink Medical, Inc. Fluid-assisted medical device
US6692491B1 (en) * 2000-03-24 2004-02-17 Scimed Life Systems, Inc. Surgical methods and apparatus for positioning a diagnostic or therapeutic element around one or more pulmonary veins or other body structures
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US6960590B2 (en) 2000-10-17 2005-11-01 Merck & Co. Inc. Orally active salts with tyrosine kinase activity
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
TWI302836B (en) 2001-10-30 2008-11-11 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
MXPA04006271A (es) 2001-12-27 2004-10-04 Theravance Inc Derivados de indolinona utiles como inhibidores de la proteina cinasa.
EP1513821B1 (en) 2002-05-23 2007-10-31 Cytopia PTY Ltd Protein kinase inhibitors
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP1546117A2 (en) 2002-08-14 2005-06-29 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
BR0313743A (pt) 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
AU2003258491A1 (en) 2002-09-05 2004-03-29 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
CA2500727A1 (en) * 2002-10-03 2004-04-15 Targegen, Inc. Vasculostatic agents and methods of use thereof
US20080207617A1 (en) 2002-10-29 2008-08-28 Kirin Beer Kabushiki Kaisha Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
BR0316229A (pt) 2002-11-13 2005-10-04 Chiron Corp Métodos de tratamento de câncer e métodos relacionados
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
EP1581526B1 (en) 2002-12-18 2009-03-11 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
MXPA05010945A (es) * 2003-04-09 2005-11-25 Japan Tobacco Inc Compuesto pentaciclico heteroaromatico y uso medicinal del mismo.
US20050113566A1 (en) * 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
MXPA05011503A (es) * 2003-04-25 2006-05-31 Johnson & Johnson Inhibidores de la c-fms cinasa.
US7790724B2 (en) * 2003-04-25 2010-09-07 Janssen Pharmaceutica N.V. c-fms kinase inhibitors
US7427683B2 (en) * 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
JP5013593B2 (ja) 2003-07-28 2012-08-29 スミスクライン ビーチャム コーポレーション 化合物
BRPI0415467A (pt) 2003-10-23 2006-12-19 Ab Science compostos de 2-aminoariloxazol para o tratamento de doenças
GB0326601D0 (en) 2003-11-14 2003-12-17 Novartis Ag Organic compounds
KR20060129413A (ko) 2004-01-30 2006-12-15 에이비 사이언스 티로신 키나제 억제제로서의2-(3-치환된-아릴)아미노-4-아릴-티아졸
NZ555289A (en) * 2004-10-22 2010-10-29 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
JP5046950B2 (ja) 2004-10-22 2012-10-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃ−ｆｍｓキナーゼのインヒビター
US7645755B2 (en) * 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
WO2006047504A1 (en) * 2004-10-22 2006-05-04 Janssen Pharmaceutica, N.V. Aromatic amides as inhibitors of c-fms kinase
DE102005023588A1 (de) 2005-05-18 2006-11-23 Grünenthal GmbH Salze substituierter Allophansäureester und deren Verwendung in Arzneimitteln
US20060281769A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281755A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20060281771A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
JP2009511628A (ja) * 2005-10-18 2009-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｆｌｔ３キナーゼの阻害方法
ES2565238T3 (es) * 2006-04-20 2016-04-01 Janssen Pharmaceutica N.V. Inhibidores de la c-fms quinasa
US8697716B2 (en) * 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
EP2021335B1 (en) * 2006-04-20 2011-05-25 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
JP5480619B2 (ja) * 2006-04-20 2014-04-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼの阻害剤

Also Published As

Publication number Publication date
BRPI0817843A2 (pt) 2015-04-07
LT3208269T (lt) 2021-11-10
DK2215079T3 (en) 2017-02-13
KR101559326B1 (ko) 2015-10-12
UA99311C2 (en) 2012-08-10
HRP20211593T1 (hr) 2022-03-18
EA201070480A1 (ru) 2010-10-29
EP2215079B1 (en) 2016-12-14
CR11433A (es) 2011-01-14
NI201000059A (es) 2010-09-13
WO2009052237A1 (en) 2009-04-23
HRP20170393T1 (hr) 2017-05-05
CA2702898C (en) 2016-10-11
IL205043A0 (en) 2010-11-30
RS55860B1 (sr) 2017-08-31
CA2702898A1 (en) 2009-04-23
MX2010004263A (es) 2010-05-03
US20090105296A1 (en) 2009-04-23
ZA201003429B (en) 2011-08-31
PL2215079T3 (pl) 2017-06-30
LT2215079T (lt) 2017-01-25
HUE031555T2 (en) 2017-07-28
EP3208269B1 (en) 2021-09-15
HUE056173T2 (hu) 2022-01-28
JP5475672B2 (ja) 2014-04-16
JP2011501752A (ja) 2011-01-13
PT2215079T (pt) 2017-03-23
CY1118717T1 (el) 2017-07-12
CL2008003068A1 (es) 2009-03-06
NZ584574A (en) 2011-12-22
TW200932738A (en) 2009-08-01
CN101889009B (zh) 2014-10-29
IL205043A (en) 2015-07-30
TWI440637B (zh) 2014-06-11
PL3208269T3 (pl) 2022-01-10
EP3208269A1 (en) 2017-08-23
CY1124721T1 (el) 2022-07-22
DK3208269T3 (da) 2021-10-11
PA8799701A1 (es) 2009-05-15
US8497376B2 (en) 2013-07-30
RS62569B1 (sr) 2021-12-31
AU2008312540A1 (en) 2009-04-23
KR20100069711A (ko) 2010-06-24
EA018936B1 (ru) 2013-11-29
CO6270363A2 (es) 2011-04-20
MY153951A (en) 2015-04-15
AU2008312540B2 (en) 2014-03-27
EP2215079A1 (en) 2010-08-11
AR068892A1 (es) 2009-12-16
PT3208269T (pt) 2021-12-09
ES2614754T3 (es) 2017-06-01
SI3208269T1 (sl) 2021-11-30
ES2905118T3 (es) 2022-04-07
BRPI0817843B1 (pt) 2019-01-02
SI2215079T1 (sl) 2017-05-31
CN101889009A (zh) 2010-11-17
BRPI0817843B8 (pt) 2021-05-25
UY31397A1 (es) 2009-04-30
JO3240B1 (ar) 2018-03-08

Similar Documents

Publication Publication Date Title
PE20090972A1 (es) Inhibidores de quinasa c-fms
PE20121480A1 (es) Aminopirimidinas como inhibidores de syk
PE20060877A1 (es) Compuestos y composiciones como inhibidores de la kinasa proteica
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20081636A1 (es) Inhibidores de antranilamida para aurora quinasa
TW200914429A (en) Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives
MY158648A (en) Compositions for modulating a kinase cascade and methods of use thereof
PE20120006A1 (es) Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
PE20040898A1 (es) Nuevos compuestos derivados de pirimidina
PE20091258A1 (es) Derivados de piridina como activadores de la guanilato ciclasa soluble
NO20084783L (no) Syntese av acylaminoalkenylenamider nyttige som substans P antagonister
PE20110136A1 (es) Compuestos organicos
PE20191757A1 (es) Compuestos heterociclicos utiles como inhibidores dobles de atx/ca
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
PE20141322A1 (es) Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina
EA200970604A1 (ru) Новое промежуточное соединение и способ, используемый для получения {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20091491A1 (es) Compuestos novedosos que son inhibidores de erk
PE20110941A1 (es) 2-[(5-cloro-2-{[3-metil-1-(1-metiletil)-1h-pirazol-5-il]amino}-4-piridinil)amino]-n-(metiloxi)benzamida como inhibidor fak
UY30533A1 (es) Acetamidas n-{1-[4(1-ciano-1-metil)fenil]etil}sustituidas derivadas del acido 2-(1h-bencimidazol-1il) acético
EA201391541A1 (ru) 5-(фенил/пиридинил-этинил)-2-пиридин/ 2-пиримидин-карбоксамиды в качестве модуляторов mglur5
PE20090243A1 (es) Compuestos de imidazol sustituido como inhibidores de renina
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
EA201100696A1 (ru) 1-(арилсульфонил)-4-(пиперазин-1-ил)-1h-бензимидазолы в качестве лигандов 5-гидрокситриптамина-6
NO20074303L (no) 7-{4-[2-(2,6-diklor-4-metylfenoksy)etoksy]fenyl}-3,9-diazabisyklo-[3.3.1]non-6-en-6-karboksylsyresyklopropyl-(2,3-dimetylbenzyl)amid som renininhibitor til behandling av hypertensjon

Legal Events

Date Code Title Description
FG Grant, registration